We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Probes Promise Exceptional Live Cell Images

By LabMedica International staff writers
Posted on 09 May 2017
Development of a new generation of chemiluminescent molecules is expected to lead to synthesis of efficient chemiluminescent probes for microscopy that will be suitable for use under physiological conditions and should provide exceptional live cell images.

Chemiluminescent probes are considered to be among the most sensitive diagnostic tools that provide high signal-to-noise ratio for various applications such as DNA detection and immunoassays.

In this regard, investigators at Tel Aviv University have developed a new molecular methodology to design and foresee light-emission properties of turn-ON chemiluminescent dioxetane probes suitable for use under physiological conditions. More...
The methodology is based on incorporation of a substituent on the benzoate species obtained during the chemiexcitation pathway of a Schaap’s adamantylidene–dioxetane probe. A striking substituent effect on the chemiluminescent efficiency of the probes was obtained when acrylate and acrylonitrile electron-withdrawing groups were installed. The chemiluminescent quantum yield of the best probe was more than three orders of magnitude higher than that of a standard, commercially available adamantylidene–dioxetane probe. These may be the most powerful chemiluminescent dioxetane probes synthesized to date that are suitable for use under aqueous conditions.

The investigators reported in the March 8, 2017, online edition of the journal ACS Central Science that one of the probes was capable of providing high-quality chemiluminescent cell images based on the endogenous activity of the enzyme beta-galactosidase. They suggested that this may have been the first demonstration of cell imaging achieved by a non-luciferin small-molecule probe with a direct chemiluminescent mode of emission.

"Chemiluminescence is considered one of the most sensitive methods used in diagnostic testing," said senior author Dr. Doron Shabat, professor of chemistry at Tel Aviv University. "We have developed a method to prepare highly efficient compounds that emit light upon contact with a specific protein or chemical. These compounds can be used as molecular probes to detect cancerous cells, among other applications."


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.